{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:57:04Z","timestamp":1781636224969,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hashimoto\u2019s encephalopathy (HE) is a rare, underdiagnosed, steroid-responsive autoimmune condition associated with thyroid autoimmunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>An 83-year-old female patient was admitted to hospital displaying symptoms of subacute cognitive decline, dysarthria and myoclonus. She had a history of Hashimoto\u2019s thyroiditis and diabetes. Given the patient\u2019s age and comorbid diabetes, the potential risks associated with steroid treatment were considered excessive. She was given an 800\u00a0mg dose of efgartigimod-\u03b1, which swiftly improved her ambulatory stability and cognitive function. Approximately four weeks later, the patient exhibited a clinical relapse and underwent a subsequent treatment cycle with efgartigimod-\u03b1. Each treatment cycle significantly alleviated the patient\u2019s symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The report under consideration herein highlights the clinical presentation, diagnostic challenges, and therapeutic considerations of HE, emphasizing the potential role of Neonatal Fc receptor (FcRn) antagonists, such as efgartigimod-\u03b1, as an emerging treatment strategy. The repeated administration of FcRn antagonists has been posited as a potential therapeutic intervention for patients diagnosed with hormone-intolerant Hashimoto\u2019s encephalopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-04699-7","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T09:16:23Z","timestamp":1771838183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent steroid-intolerant Hashimoto\u2019s encephalopathy responsive to single-dose neonatal Fc receptor antagonist: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-7497","authenticated-orcid":false,"given":"Xiangliang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3604-2611","authenticated-orcid":false,"given":"Ruile","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"4699_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/s0140-6736(66)92876-5","volume":"2 7462","author":"L Brain","year":"1966","unstructured":"Brain L, Jellinek EH, Ball K. Hashimoto\u2019s disease and encephalopathy. Lancet. 1966;2 7462:512\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(66)92876-5.","journal-title":"Lancet"},{"key":"4699_CR2","doi-asserted-by":"publisher","unstructured":"Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003;60. https:\/\/doi.org\/10.1001\/archneur.60.2.164. 2:164\u2009\u2013\u200971.","DOI":"10.1001\/archneur.60.2.164"},{"key":"4699_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jns.2003.09.007","volume":"217 2","author":"F Ferracci","year":"2004","unstructured":"Ferracci F, Bertiato G, Moretto G. Hashimoto\u2019s encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci. 2004;217 2:165\u20138. https:\/\/doi.org\/10.1016\/j.jns.2003.09.007.","journal-title":"J Neurol Sci"},{"key":"4699_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00023210-200721100-00002","volume":"21 10","author":"R Mocellin","year":"2007","unstructured":"Mocellin R, Walterfang M, Velakoulis D. Hashimoto\u2019s encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007;21 10:799\u2013811. https:\/\/doi.org\/10.2165\/00023210-200721100-00002.","journal-title":"CNS Drugs"},{"key":"4699_CR5","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.autrev.2016.01.014","volume":"15 5","author":"G Montagna","year":"2016","unstructured":"Montagna G, Imperiali M, Agazzi P, D\u2019Aurizio F, Tozzoli R, Feldt-Rasmussen U, et al. Hashimoto\u2019s encephalopathy: A rare proteiform disorder. Autoimmun Rev. 2016;15 5:466\u201376. https:\/\/doi.org\/10.1016\/j.autrev.2016.01.014.","journal-title":"Autoimmun Rev"},{"key":"4699_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(15)00401-9","volume":"15 4","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15 4:391\u2013404. https:\/\/doi.org\/10.1016\/s1474-4422(15)00401-9.","journal-title":"Lancet Neurol"},{"key":"4699_CR7","doi-asserted-by":"publisher","unstructured":"Dalmau J, Graus F. Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease. Lancet Neurol. 2023;22. https:\/\/doi.org\/10.1016\/s1474-4422(23)00083-2. 6:529\u2009\u2013\u200940.","DOI":"10.1016\/s1474-4422(23)00083-2"},{"key":"4699_CR8","doi-asserted-by":"publisher","first-page":"8e70280","DOI":"10.1111\/ene.70280","volume":"32","author":"Z Bi","year":"2025","unstructured":"Bi Z, Kang W, Liu R, Jiang Y, Chen M. Efgartigimod as a Fast-Acting Add-On therapy in Antibody-Mediated autoimmune encephalitis. Eur J Neurol. 2025;32:8e70280. https:\/\/doi.org\/10.1111\/ene.70280.","journal-title":"Eur J Neurol"},{"key":"4699_CR9","doi-asserted-by":"publisher","first-page":"8e70534","DOI":"10.1111\/cns.70534","volume":"31","author":"Z Bian","year":"2025","unstructured":"Bian Z, Cai H, Wu H, Liu P, Zuo Y, Peng F, et al. Safety and efficacy of a neonatal Fc receptor antagonist in patients with Anti-NMDAR encephalitis. CNS Neurosci Ther. 2025;31:8e70534. https:\/\/doi.org\/10.1111\/cns.70534.","journal-title":"CNS Neurosci Ther"},{"key":"4699_CR10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s10072-024-07460-5","volume":"45 9","author":"Y Yang","year":"2024","unstructured":"Yang Y, Shen Z, Shi F, Wang F, Wen N. Efgartigimod as a novel FcRn inhibitor for autoimmune disease. Neurol Sci. 2024;45 9:4229\u201341. https:\/\/doi.org\/10.1007\/s10072-024-07460-5.","journal-title":"Neurol Sci"},{"key":"4699_CR11","doi-asserted-by":"publisher","unstructured":"Heo YA. Efgartigimod Alfa in generalised myasthenia gravis: A profile of its use. CNS Drugs. 2023;37. https:\/\/doi.org\/10.1007\/s40263-023-01000-z. 5:467\u2009\u2013\u200973.","DOI":"10.1007\/s40263-023-01000-z"},{"key":"4699_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","volume":"46 5","author":"J Xu","year":"2025","unstructured":"Xu J, Guo Z, Zhao J, Chen Y, Liu Z, Wu Y. Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review. Neurol Sci. 2025;46 5:1995\u20132005. https:\/\/doi.org\/10.1007\/s10072-024-07843-8.","journal-title":"Neurol Sci"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04699-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:41:14Z","timestamp":1781635274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4699"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04699-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish this information was obtained from the patient and his legal guardians. The manuscript has been approved by all authors for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}